Lexeo Therapeutics LXEO
NASDAQ LXEO
$4.90 +0.06 (+1.24%)
As of: Sep 4, 2026 · 3:55 PM EDT

Lexeo Therapeutics (LXEO) Non Operating Interest Expenses (2022 - 2026)

Analysis

Lexeo Therapeutics (LXEO) Non Operating Interest Expenses (2022 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 11.00 Mn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -1.00 Mn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -
5 Revolution Medicines 44.33 Bn 44.33 Bn - 23.78 Mn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 39.74 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 82.05 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 93.62 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 20.27 Mn
10 Lexeo Therapeutics 419.14 Mn 419.14 Mn - 14,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 14,000.00
Mar 31, 2026 17,000.00
Dec 31, 2025 20,000.00
Sep 30, 2025 22,000.00
Jun 30, 2025 25,000.00
Mar 31, 2025 28,000.00
Dec 31, 2024 30,000.00
Sep 30, 2024 35,000.00
Jun 30, 2024 35,000.00
Mar 31, 2024 37,000.00
Dec 31, 2023 50,000.00
Sep 30, 2023 52,000.00
Jun 30, 2023 53,000.00
Mar 31, 2023 50,000.00
Dec 31, 2022 54,000.00
Sep 30, 2022 29,000.00